Plus Therapeutics Inc. has granted stock options and restricted stock units (RSUs) to two new hires, Mr. Gurnani and Ms. Luckey, at its CNSide Diagnostics subsidiary. Each employee received options to purchase up to 33,750 shares of the company's common stock at the closing price on December 4, 2025. The options are set to vest over four years, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments, contingent on continued employment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9598813) on December 09, 2025, and is solely responsible for the information contained therein.